LL-37
Cathelicidin / Human Cathelicidin / hCAP-18
LL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino acid cationic peptide cleaved from its precursor protein hCAP-18 by proteinase 3 in neutrophils and various epithelial cells. It serves as a critical component of the innate immune system, providing broad-spectrum antimicrobial activity against bacteria, viruses, and fungi while also modulating inflammation and promoting wound healing. LL-37 expression is upregulated by vitamin D3, which mechanistically explains many of vitamin D's documented immune-enhancing effects.
作用機序
Endogenous human antimicrobial peptide cleaved from cathelicidin precursor hCAP-18. Disrupts microbial membranes, neutralizes endotoxin (LPS), modulates TLR signaling, promotes wound healing via angiogenesis, and recruits immune cells through chemotactic activity.
研究プロトコル
研究目的のみで使用。医療アドバイスではありません。
Research protocols use 50-100mcg subcutaneously daily. Topical applications for wound healing at 10-50mcg/ml. Intranasal protocols studied for upper respiratory infections. Cycles of 1-4 weeks.
研究ノート
Clinical Research Status
LL-37 is actively being investigated in clinical trials for chronic wound healing, with a Phase I/II trial (by Promore Pharma, now Lipigon) demonstrating safety and efficacy in venous leg ulcers. Research applications span chronic infections, biofilm-associated conditions, diabetic wound healing, and as a topical antimicrobial agent. No systemic injectable formulation has reached clinical trials due to challenges with peptide stability and potential hemolytic activity at high systemic concentrations. The connection between vitamin D deficiency and susceptibility to infections has driven research into LL-37 as the mechanistic link.
Key Published Findings
LL-37 demonstrates broad-spectrum antimicrobial activity against gram-positive and gram-negative bacteria, including MRSA and Pseudomonas aeruginosa, through membrane disruption mechanisms. A landmark 2006 Science paper showed LL-37 disrupts bacterial biofilms at sub-MIC concentrations by interfering with biofilm attachment and stimulating twitching motility. Research in the Journal of Immunology demonstrated LL-37 acts as a chemoattractant for neutrophils, monocytes, and T-cells through formyl peptide receptor-like 1 (FPRL1) activation. Studies show vitamin D supplementation increases LL-37 expression 3-5 fold in human macrophages, establishing a direct molecular link between vitamin D status and innate immunity.
Safety Profile
Topical application of LL-37 has been well-tolerated in clinical wound healing trials with no serious adverse events reported. At high systemic concentrations, LL-37 can exhibit cytotoxicity to mammalian cells and hemolytic activity, limiting its use as a systemic injectable. Local injection site reactions including redness and transient pain have been reported but resolve within hours. The peptide is rapidly degraded by serum proteases, which provides a natural safety mechanism against systemic accumulation but limits bioavailability.
Drug Interactions & Contraindications
High-dose vitamin D supplementation increases endogenous LL-37 production and may have additive effects when combined with exogenous LL-37 administration. Concurrent use with other membrane-active antimicrobials (daptomycin, polymyxins) could theoretically produce synergistic cytotoxicity requiring dose adjustment. Patients with rosacea or psoriasis may have elevated endogenous LL-37 levels contributing to their pathology, and exogenous administration could exacerbate these conditions. Not recommended for patients with systemic lupus erythematosus as LL-37-DNA complexes may activate plasmacytoid dendritic cells and worsen autoimmune responses.
Comparison to Related Compounds
Unlike conventional antibiotics, LL-37 kills bacteria through physical membrane disruption, making resistance development extremely difficult compared to target-specific drugs. Compared to other antimicrobial peptides (defensins, magainins), LL-37 is unique in its additional immunomodulatory, angiogenic, and wound-healing properties beyond direct microbial killing. Relative to KPV (another immune peptide), LL-37 is primarily antimicrobial and pro-healing while KPV is primarily anti-inflammatory. Its biofilm-disrupting properties distinguish it from virtually all conventional antibiotics, which are ineffective against established biofilms.
Community Observations
Users primarily employ LL-37 topically or via local subcutaneous injection near chronic wounds, infections, or biofilm-associated conditions at doses ranging from 50-200 mcg. Reports suggest benefit for chronic sinusitis, Lyme disease co-infections, and recurrent skin infections where biofilm involvement is suspected. Many users supplement with vitamin D3 (5,000-10,000 IU daily) to simultaneously boost endogenous LL-37 production alongside exogenous administration. The peptide is considered poorly suited for systemic injection due to rapid degradation and is most often used in targeted, localized applications.
半減期
~4-6 hours
再構成
Sterile water or bacteriostatic water
保存
乾燥粉末
Store at -20C for long term.
再溶解
Refrigerate 2-8C. Use within 7 days.
米国法的状況
また知られる名前
よくある質問
LL-37とは何ですか?
LL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino acid cationic peptide cleaved from its precursor protein hCAP-18 by proteinase 3 in neutrophils and various epithelial cells. It serves as a critical component of the innate immune system, providing broad-spectrum antimicrobial activity against bacteria, viruses, and fungi while also modulating inflammation and promoting wound healing. LL-37 expression is upregulated by vitamin D3, which mechanistically explains many of vitamin D's documented immune-enhancing effects.
LL-37はどのように作用しますか?
Endogenous human antimicrobial peptide cleaved from cathelicidin precursor hCAP-18. Disrupts microbial membranes, neutralizes endotoxin (LPS), modulates TLR signaling, promotes wound healing via angiogenesis, and recruits immune cells through chemotactic activity.
LL-37の米国での規制状況は?
Research chemical (not FDA-approved)
LL-37の半減期は?
~4-6 hours
LL-37の別名は?
Cathelicidin, Human Cathelicidin, hCAP-18
ペプチドコンタクトは、研究目的のみのための要約情報を提供しています。私たちはベンダーの文書をホスト、配布、または推奨していません。すべての分析証明書、GMP認定証明書、およびベンダーコミュニケーションは、購入者によって直接要求され、確認される必要があります。このプラットフォーム上の何らかの情報は法的、医学的、または専門的なアドバイスを構成していません。ユーザーは、適切な法律、州法、および連邦法に準拠するためにベンダー資格を検証し、購入前に遵守することに全責任を持つ必要があります。このプラットフォームを使用することで、完全な個人的責任を承認することになります。
完全な免責事項を読む